Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment.
García-Pinel B, Porras-Alcalá C, Ortega-Rodríguez A, Sarabia F, Prados J, Melguizo C, López-Romero JM. · 2019
Read Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment. by García-Pinel B, Porras-Alcalá C, Ortega-Rodríguez A, Sarabia F, Prados J, Melguizo C, López-Romero JM. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6523119.txt.
Introduction
García-Pinel and co-authors review lipid-based nanoparticles for cancer treatment. Their review appeared in Nanomaterials. Many cancer drugs dissolve poorly, break down fast, or cause harsh side effects. Lipid carriers can shield such drugs and guide them.
Types covered include liposomes, solid lipid nanoparticles and nanostructured lipid carriers. These systems hold both water-loving and fat-loving drugs. They offer high loading, long stability and low cost. Loading a drug into them can cut the dose and toxicity. More drug reaches tumour tissue and less reaches healthy tissue. Drug resistance may also fall. The authors sum up lab, animal and patient trial results.
Catalog record
| CREATOR | García-Pinel B, Porras-Alcalá C, Ortega-Rodríguez A, Sarabia F, Prados J, Melguizo C, López-Romero JM. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 74 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment By Beatriz García-Pinel, Cristina Porras-Alcalá, Alicia Ortega-Rodríguez, Francisco Sarabia, Jose Prados, Consolación Melguizo, Juan M. López-Romero Published in: Nanomaterials DOI: 10.3390/nano9040638 ABSTRACT Many therapeutically active molecules are non-soluble in aqueous systems, chemically and biologically fragile or present severe side effects. Lipid-based nanoparticle (LBNP) systems represent one of the most promising colloidal carriers for bioactive organic molecules. Their current application in oncology has revolutionized cancer treatment by improving the antitumor activity of several chemotherapeutic agents. LBNPs advantages include high temporal and thermal stability, high loading capacity, ease of preparation, low production costs, and large-scale industrial production since they can be prepared from natural sources. Moreover, the association of chemotherapeutic agents with lipid nanoparticles reduces active therapeutic dose and toxicity, decreases drug resistance and increases drug levels in tumor tissue by decreasing them in healthy tissue. LBNPs have been extensively assayed in in vitro cancer therapy but also in vivo, with promising results in some clinical trials. This review summarizes the types of LBNPs that have been developed in recent years and the main results when applied in cancer treatment, including essential assays in patients. 1. INTRODUCTION Cancer nanotechnology as a way of anticancer drug delivery has been developed as a promising cancer treatment [1]. Nanoparticles present sizes between 1 and 1000 nm and they improve drug bioavailability as well as the selectivity of the anticancer drug [2]. Among many nanoformulations used in oncology, we highlight those based on lipid formulations, since great advances have been made in recent years with respect to preparation and alternative compositions [3]. Lipid-based nanoparticles (LBNPs) such as liposomes, solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) have received great attention in drug discovery and cancer treatment. These nanoparticles can transport hydrophobic and hydrophilic molecules, display very low or no toxicity, and increase the time of drug action by means of a prolonged half-life and a controlled release of the drug [4]. Lipid nanosystems can include chemical modifications to avoid the detection by the immune system (gangliosides or polyethylene glycol (PEG)) or to improve the solubility of the drug. In addition, they can be prepared in formulations sensitive to the pH in order to promote drug release in an acid environment, and can also be associated with antibodies that recognize tumor cells or their receptors (such as folic acid (FoA)) [5]. Nanodrugs can also be used in combination with other therapeutic strategies to improve the response of patients. Many antitumor agents, such as cisplatin, irinotecan (IRI), paclitaxel (PTX), doxorubicin (DOX) oxaliplatin, daunorubicin, cytarabine or vincristine, have been studied in nanoformulations, and some of them have been analyzed in clinical trials and/or are commercially available for clinical use in patients [6]. In fact, Doxil®, a liposome formulation encapsulating DOX, was one of the first anticancer drug nanosystems commercially used. This review highlights the main contributions to LBNPs that have been developed in recent years and applied in cancer treatment, including essential assays in patients. 2. LIPID-BASED NANOPARTICLES 2.1. Liposomes Liposomes are the most studied delivery systems due to the biocompatibility and biodegradability that they present. The main components of these nanoparticles are phospholipids, which are organized in a bilayer structure due to their amphipathic properties. In presence of water, they form vesicles, improving the solubility and stability of anticancer drugs once they are loaded into their structure. They are capable of encapsulating either hydrophobic or hydrophilic drugs [7]. In addition to phospholipids, other compounds can be added to their formulations, such as cholesterol, which decreases the fluidity of the nanoparticle and increases the permeability of hydrophobic drugs through the bilayer membrane, improving the stability of these nanoparticles in blood [7]. Cholesterol-modified liposomes may present a multiple bilayer with sizes from 0.5 nm to 10 nm, named Multilaminar Vesicles (MLVs); a single bilayer with sizes above 100 nm, named Large Unilamellar Vesicles (LUVs); and intermediate sizes (10–100 nm), which are called Small Unilamellar Vesicles (SUVs) [7]. It is well known that there are two general ways to achieve nanocarrier vectorization. One of them is passive targeting, which occurs when liposomes only enter the tumor cell by molecular movement through the cellular membrane. The other is active targeting, which involves structurally modified liposomes holding antibodies that recognize tumor cells [8]. A third method can be considered for liposomes, which is when they have been prepared with stimulus-sensitive structures. Temperature, pH or magnetic fields are parameters that can be modulated for the controlled delivery of an anticancer drug by using an external trigger [9]. The synthesis and development of new liposomes have been extensively studied in recent years. In fact, Fe3O4 cores are increasingly being used to functionalize different types of nanoparticles (Figure 1). In 2014, chemotherapy and hyperthermia treatment were combined by using liposome-encapsulated DOX, which included citric acid-coated magnetic nanoparticles [10]. Also in 2014, DOX was co-encapsulated with Magnevist®, a contrast agent; both actives were included in a liposome modified with amphiphilic hyaluronic acid and cholesterol [11]. Moreover, ultrasound-sensitive liposomes were developed for DOX encapsulation [12], such as in the case of the thermo-sensitive polymer poly(NIPMAM-co-NIPAM), which can be degraded by sonication, leading to drug release. On the other hand, liposomes modified with PEG and anacardic acid have been developed, and these were employed to encapsulate docetaxel, improving the stability of this anticancer drug [13]. Yan et al. [14] developed a pH-responsive liposome coated with a glycol derivative chitosan. These liposomes presented terminal amine groups, which conferred a superficial negative charge to interact with the positive charge present in the acidic extracellular tumor media. DOX was loaded into this liposome, and a remarkable improvement of its anticancer efficacy was observed [14]. Ramadass et al. [15] co-encapsulated epigallocatechin gallate (a type of catechin) and PTX in this type of liposome for the treatment of lung cancer. In vivo studies showed that this liposome-based treatment was more effective compared with treatments with free drugs [15]. Ali et al. [16] synthetized a PEGylated liposome, whereby they encapsulated doxorrubicin hydrochloride instead of DOX. This new liposome-based formulation of DOX proved to be safe and effective against ovarian cancer [16]. In this year, another PEGylated liposome was developed by Meng et al. [17] with a size of 50 nm to co-encapsulate two different anticancer drugs, resveratrol and PTX, as a novel delivery system to combat the resistance of cancer. On the other hand, Xiao et al. [18] developed a liposome modified with gadolinium to improve the solubility of sorafenib, an anticancer drug with low solubility in water. Additionally, they studied this system of anticancer drug delivery in vivo as well as in vitro, demonstrating that this liposome could also be applied as a contrast agent [18]. Gogoi et al. [8] explored novel magnetic liposomes. To this end, they co-encapsulated dextran, La0.75Sr0.25MnO3 and iron oxide to combine self-controlled hyperthermia and chemotherapy. PTX was encapsulated in this type of hybrid liposome. In vitro and in vivo biological studies demonstrated the biocompatibility and therapeutic efficacy of this new magnetic liposome [8]. In 2018, various liposomes were developed to encapsulate different anticancer drugs. For example, Sushant Lakkadwala et al. [19] designed a liposome modified with penetrating peptides and transferrin to encapsulate 5-fluorouracil (5-FU) for the treatment of brain